Table 1 Demographics and clinical variables of the study participants
From: Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity
Variables | GWAS | Replication study | ||||
|---|---|---|---|---|---|---|
| Â | DILI Cases | Treatment tolerants | P | DILI cases | Treatment tolerants | P |
No. of patients | 48 | 354 | - | 27 | 217 | - |
Sex (M, F) | 19, 29 | 203, 151 | 0.02 | 12, 15 | 85, 132 | 0.60 |
Age (yr), M (SD) | 35.6 (10.4) | 35.7 (11.5) | 0.93 | 32.0 (7.4) | 33.4 (10.3) | 0.48 |
BMI (kg/m2), M (SD) | 19.0 (3.2) | 19.3 (3.0) | 0.55 | 17.5 (3.0) | 18.9 (3.0) | 0.02 |
HIV positive, N (%) | 44 (91.7) | 225 (63.6) | <0.01 | 25 (92.6) | 158 (72.8) | 0.03 |
CD4 count, M (SD) | 96.6 (78.5) | 129.3 (120.8) | 0.03 | 116.8 (98.3) | 138.2 (121.0) | 0.33 |
Viral load, log M (SD) | 5.3 (0.9) | 4.9 (0.9) | 0.03 | 5.0 (0.8) | 4.9 (0.9) | 0.54 |
ALT (U/L), M (SD) | 69.7 (37.2) | 30.4 (14.4) | <0.01 | 67.2 (42.1) | 30.7 (14.1) | <0.01 |
AST (U/L), M (SD) | 101.2 (52.7) | 40.5 (16.2) | <0.01 | 103.6 (71.9) | 38.7 (13.6) | <0.01 |
ALP (U/L), M (SD) | 187.7 (72.2) | 121.1 (51.7) | <0.01 | 225.8 (139.9) | 114.0 (63.1) | <0.01 |
T Bil (mg/dL), M (SD) | 1.2 (1.0) | 0.6 (0.4) | <0.01 | 1.1 (0.7) | 0.5 (0.3) | <0.01 |
DILI pattern, N (%) | ||||||
 Cholestatic | 19 (39.6) |  |  | 15 (55.6) |  |  |
 Hepatocellular | 10 (20.8) |  |  | 5 (18.5) |  |  |
 Mixed | 19 (39.6) |  |  | 7 (25.9) |  |  |